Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

secukinumab (Cosentyx)

secukinumab is an FDA-licensed reference biologic from Novartis Pharmaceuticals Corporation.

351(a) biologicBLA 125504 Novartis Pharmaceuticals Corporation
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2021

Reference product

Originator biologic
351(a)BLA 125504

Cosentyx secukinumab

Novartis Pharmaceuticals Corporation

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for secukinumab from the RCSB Protein Data Bank (PDB 9SFX).

3D molecular structure of secukinumab (PDB entry 9SFX)

Interactive biological assembly from PDB entry 9SFX. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference secukinumab product.

    5 yr 5 mo ago

secukinumab: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for secukinumab.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.